Clinical trials: PSMA PET
Prostate Cancer
Ga-68 PSMA PET/CT vs mpMRI in Cognitive Prostate Biopsy
Prostate cancer is the most common malignancy among elderly men. With the routine use of prostate-specific antigen (PSA) testing since the 1980s, the incidence of prostate cancer has significantly increased.
- Trial name
- PSMA-MRI BX (NCT07533344)
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Fatih Sultan Mehmet Training and Research Hospital
Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases From Melanoma
Novel Ga68-PSMA PET/CT-tracer to Differentiate Between Radiation Necrosis and Tumor Progression in Brain Metastases
This study aims to evaluate the diagnostic potential of 68-Gallium PSMA-PET/CT in stereotactic irradiated brain metastases from non-small cell lung cancer, melanoma and breast cancer.
- Conditions
- Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases From Melanoma, Brain Metastases From Breast Cancer
- Trial name
- NCT07511933
- Testing
- 86-Gallium PSMA PET/CT
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- The Netherlands Cancer Institute
Prostate Cancer
Biodistribution and Pharmacokinetic Study of 18F-DCFBC Prostate Specific Membrane Antigen Based PET in Patients With Advanced Prostate Cancer
Prostate cancer is the most common cancer among men in the United States. Through early detection and improved local therapies a large number of men will be cured.
- Trial name
- NCT01417182
- Testing
- 18F-DCFBC
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Comparing PSMA PET/CT and MRI-RSI for Finding and Outlining Tumors Inside the Prostate in Men With Newly Diagnosed Prostate Cancer
The detection and delineation of the intraprostatic tumor burden plays a crucial role in the personalized treatment of primary prostate cancer.
- Trial name
- PRIDE2-PC (NCT07568613)
- Testing
- MRI, 18F-PSMA1007 PET-CT, MR-guided TRUS Prostate biopsy
- Where
- Cyprus
- Volunteers
- 50 people
- Sponsor
- German Oncology Center, Cyprus
Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer
This phase I trial tests the safety, side effects and best dose of radioligand therapy (lutetium Lu 177 PSMA-10.1 [177Lu-rhPSMA-10.1]) after prostate specific membrane antigen (PSMA) positron emission tomography (PET)-guided…
- Trial name
- NCT06105918
- Testing
- Biospecimen Collection, Computed Tomography, External Beam Radiation Therapy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Emory University
PSMA PET/CT, Prostate Cancer
The Diagnostic Application of PSMAPET/MR in Patients Undergoing Secondary Prostate Puncture
The present study is designed to explore the value of targeted puncture guided by PSMA PET/CT or mpMRI in the diagnosis of patients with low PSA and initial negative prostate biopsy
- Conditions
- PSMA PET/CT, Prostate Cancer, MpMRI
- Trial name
- NCT06901492
- Testing
- Prostate biopsy guided by PSMA PET/CT, Prostate biopsy guided by mpMRI/US, Systematic prostate biopsy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Prostate Cancer
Evaluation of Prostate-specific Membrane Antigen (PSMA)-Based PET Imaging of Primary Prostate Cancer
The objective of this study is to evaluate a radiolabeled urea-based small molecule inhibitor of prostate-specific membrane antigen (PSMA), [18F]DCFBC (DCFBC), as a PET imaging biomarker of prostate cancer detection and…
- Trial name
- NCT01496157
- Testing
- 18F-DCFBC
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Neoplasms
Evaluating the Role of Both PSMA and 64Cu-PET/CT Total Body in Patients With Locally Relapsed Prostate Cancer
The purpose of this study is to assess the detection rate of local relapse after radical prostatectomy with either PSMA or 64Cu-PET/CTs and whether the delineation of relapsed lesions using both methods can facilitate/change the…
- Trial name
- NCT04703543
- Testing
- Pilot evaluation study on use PSMA and Cu-PET/CT
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Regina Elena Cancer Institute
Prostate Cancer
Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET
The purpose of this prospective cohort study is to investigate the role of Fluciclovine Positron Emission Tomography (PET) in patients with biochemical recurrence of prostate cancer (BCR) and a negative Prostate Specific Membrane…
- Trial name
- NCT05722925
- Testing
- Fluciclovine PET/CT
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- OHSU Knight Cancer Institute
Radionucleide Therapy
Pre-therapeutic 68Ga-PSMA PET AI Based Dose Prediction for 177Lu-PSMA Targeted Radionuclide Therapy
Targeted Radionuclide Therapy (TRT) is a contemporary approach to radiation oncology, aiming to deliver the maximal destructive radiation dose via cancer-targeting radiopharmaceutical.
- Trial name
- PADL (NCT06268418)
- Testing
- Artificial intelligence
- Where
- 2 sites in France
- Volunteers
- 46 people
- Sponsor
- Central Hospital, Nancy, France
Prostate Cancer
Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer
This study evaluates the rate of radiological disease progression with the new 2nd generation positron emission tomography (PET) radiopharmaceutical, 18F-DCFPyL, in patients with metastatic castration (mCRPC) and non-metastatic…
- Trial name
- NCT03800784
- Testing
- 18F-DCFPyL Injection
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy
This clinical trial studies how well gallium Ga 68-labeled prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET)/computed tomography (CT) works in detecting prostate cancer that has come back (recurrent)…
- Trial name
- NCT02940262
- Testing
- Gallium Ga 68 Gozetotide, Laboratory Biomarker Analysis, Positron Emission Tomography
- Where
- United States
- Volunteers
- 1,138 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
Single-Dose Image-Guided Radiotherapy With Urethral Sparing and DIL Boost for Intermediate-Risk Prostate Cancer (PROSINT II)
This prospective single-arm phase II study evaluates the safety, feasibility, quality-of-life effects, PSA kinetics, imaging response, and clinical outcomes of definitive ultra-high dose single-fraction external beam radiation…
- Trial name
- PROSINT II (NCT04035642)
- Testing
- IGRT-VMAT / SDRT 24 Gy in 1 fraction, Rectal balloon with air filling, Urethral catheter loaded with beacon transponders
- Where
- Portugal
- Volunteers
- 200 people
- Sponsor
- Fundacao Champalimaud
Prostate Cancer
Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy
Broadly, the objective of this study is to evaluate the fractional decline of intensity of tracer uptake measured by SUVmax on 68Ga-PSMA PET/CT in bone metastases from prostate cancer following treatment with radium-223 as a…
- Trial name
- NCT03062254
- Testing
- radium-223 dichloride
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8
Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial
This phase II trial studies how well a short course of androgen deprivation therapy (ADT) with relugolix works in increasing expression of prostate-specific membrane antigen (PSMA) and improving diagnostic imaging with PSMA…
- Conditions
- Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
- Trial name
- NCT07025369
- Testing
- Biospecimen Collection, Computed Tomography, Flotufolastat F-18 Gallium
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic